论文部分内容阅读
目的探讨89SrCl2联合内分泌治疗对晚期前列腺癌疼痛及骨转移瘤的疗效。方法将68例骨扫描呈单发或多发转移灶的晚期前列腺癌患者分为联合组和内分泌治疗组,各34例。联合组采用89SrCl2联合内分泌治疗,内分泌治疗组行单纯内分泌治疗,治疗3个月后骨扫描检查,了解转移灶情况,测定前列腺素E(2PGE2)浓度。结果联合组骨痛缓解的总有效率高于内分泌治疗组(88.2%58.8%,﹤0.05)。联合组PGE2明显下降,与内分泌治疗组比较差异有显著性意义(﹤0.05)。两组患者骨转移病灶出现不同程度的好转,其中联合组67.6%患者骨转移灶不同程度缩小,密度变淡或者消失,内分泌治疗组为41.2%(﹤0.05)。结论89SrCl2联合内分泌治疗能改善前列腺癌骨转移引起的疼痛,而且可以破坏骨肿瘤,使转移灶缩小或消失,疗效优于单纯内分泌治疗。
Objective To investigate the effect of 89SrCl2 combined with endocrine therapy on advanced prostate cancer pain and bone metastases. Methods Sixty-six patients with advanced prostate cancer with single or multiple bone metastases were divided into combined group and endocrine therapy group, 34 cases in each group. The combined group was treated with 89SrCl2 combined with endocrine therapy. The endocrine therapy group was treated with endocrine therapy alone. After 3 months of treatment, the bone scan was performed to understand the metastasis and to determine the concentration of prostaglandin E (2PGE2). Results The total effective rate of bone pain relief in combination group was higher than that in endocrine therapy group (88.2%, 58.8%, <0.05). PGE2 in the combined group was significantly decreased compared with the endocrine therapy group was significant (P <0.05). Two groups of patients with bone metastasis lesions improved to varying degrees, of which 67.6% of patients with joint bone metastases shrink to varying degrees, the density fades or disappeared, the endocrine therapy group was 41.2% (<0.05). Conclusion 89SrCl2 combined with endocrine therapy can improve the pain caused by bone metastasis of prostate cancer, and can destroy bone tumors, the metastasis shrink or disappear, the effect is better than the simple endocrine therapy.